These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 28397696)

  • 1. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    European Union HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?
    Kondili LA; Robbins S; Blach S; Gamkrelidze I; Zignego AL; Brunetto MR; Raimondo G; Taliani G; Iannone A; Russo FP; Santantonio TA; Zuin M; Chessa L; Blanc P; Puoti M; Vinci M; Erne EM; Strazzabosco M; Massari M; Lampertico P; Rumi MG; Federico A; Orlandini A; Ciancio A; Borgia G; Andreone P; Caporaso N; Persico M; Ieluzzi D; Madonia S; Gori A; Gasbarrini A; Coppola C; Brancaccio G; Andriulli A; Quaranta MG; Montilla S; Razavi H; Melazzini M; Vella S; Craxì A;
    Liver Int; 2018 Dec; 38(12):2190-2198. PubMed ID: 29900654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.
    Polaris Observatory HCV Collaborators
    Lancet Gastroenterol Hepatol; 2022 May; 7(5):396-415. PubMed ID: 35180382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
    Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
    Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global prevalence of hepatitis C virus in children in 2018: a modelling study.
    Schmelzer J; Dugan E; Blach S; Coleman S; Cai Z; DePaola M; Estes C; Gamkrelidze I; Jerabek K; Ma S; Montoya S; Razavi-Shearer D; Razavi-Shearer K; Robbins-Scott S; Razavi H; El Sayed MH
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):374-392. PubMed ID: 31954439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Securing sustainable funding for viral hepatitis elimination plans.
    Hatzakis A; Lazarus JV; Cholongitas E; Baptista-Leite R; Boucher C; Busoi CS; Deuffic-Burban S; Chhatwal J; Esmat G; Hutchinson S; Malliori MM; Maticic M; Mozalevskis A; Negro F; Papandreou GA; Papatheodoridis GV; Peck-Radosavljevic M; Razavi H; Reic T; Schatz E; Tozun N; Younossi Z; Manns MP
    Liver Int; 2020 Feb; 40(2):260-270. PubMed ID: 31808281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
    Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
    J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study.
    Dugan E; Blach S; Biondi M; Cai Z; DePaola M; Estes C; Feld J; Gamkrelidze I; Kottilil S; Ma S; Mathur P; Montoya S; Razavi-Shearer D; Razavi-Shearer K; Robbins-Scott S; Schmelzer J; Razavi H
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):169-184. PubMed ID: 33515496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
    Papatheodoridis GV; Hatzakis A; Cholongitas E; Baptista-Leite R; Baskozos I; Chhatwal J; Colombo M; Cortez-Pinto H; Craxi A; Goldberg D; Gore C; Kautz A; Lazarus JV; Mendão L; Peck-Radosavljevic M; Razavi H; Schatz E; Tözün N; van Damme P; Wedemeyer H; Yazdanpanah Y; Zuure F; Manns MP
    J Viral Hepat; 2018 Mar; 25 Suppl 1():6-17. PubMed ID: 29508946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
    J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets.
    Petkevičienė J; Voeller A; Čiupkevičienė E; Razavi-Shearer D; Liakina V; Jančorienė L; Kazėnaitė E; Zaksas V; Urbonas G; Kupčinskas L
    BMC Public Health; 2024 Apr; 24(1):1055. PubMed ID: 38622549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
    Kondili LA; Blach S; Razavi H; Craxì A
    Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.
    Polaris Observatory HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):161-176. PubMed ID: 28404132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global timing of hepatitis C virus elimination in high-income countries.
    Razavi H; Sanchez Gonzalez Y; Yuen C; Cornberg M
    Liver Int; 2020 Mar; 40(3):522-529. PubMed ID: 31815353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C.
    Sulkowski M; Cheng WH; Marx S; Sanchez Gonzalez Y; Strezewski J; Reau N
    Adv Ther; 2021 Jan; 38(1):423-440. PubMed ID: 33145648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries.
    Falla AM; Ahmad AA; Duffell E; Noori T; Veldhuijzen IK
    BMC Infect Dis; 2018 Jan; 18(1):42. PubMed ID: 29338702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
    PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of Hepatitis C Virus in Australia: Laying the Foundation.
    Dore GJ; Hajarizadeh B
    Infect Dis Clin North Am; 2018 Jun; 32(2):269-279. PubMed ID: 29778255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.